BPG is committed to discovery and dissemination of knowledge
Case Control Study
Copyright: ©Author(s) 2026.
World J Nephrol. Jun 25, 2026; 15(2): 118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877
Figure 1
Figure 1 Flowchart assessment of patients with metabolic dysfunction-associated steatotic disease. The basic assessment helped differentiate patients into those with and without type-2 diabetes mellitus. Additionally, specific assessments exhibited a significant association between metabolic dysfunction-associated steatotic disease, diabetes mellitus, and increased chronic kidney disease stage. MASLD: Metabolic dysfunction-associated steatotic disease; DM: Diabetes mellitus; CKD: Chronic kidney disease; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance.


Write to the Help Desk